Taking Stelara By Stealth? Amgen Stays Silent On US Ustekinumab Launch

All Quiet On The Wezlana Front As Amgen Declines To Offer Any Details

 
• By Dave Wallace
  
Amgen is keeping quiet over its Wezlana launch

More from Biosimilars

More from Generics Bulletin